Table 1.
Furazolidone-Amoxicillin–bismuth quadruple therapy
| Year | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bismuth (BPC) | Furazolidone | Amoxicillin | PPI | Days | ITT | PP% | ||||||||
| O/P | Dose | N | % | N | % | |||||||||
| 2004 | Tehran | 240 b.i.d | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 50 | 72 | 49 | 73.4 | UBT | Side effect (n=1) | [21] |
| 2009 | Shiraz | 240 b.i.d. | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 69 | 49 | 60 | 56 | UBT | Lost (n=9) | [28] |
| 2009 | Zaheda n | 200 q.i.d. | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 49 | 85.7 | 49 | 85.7 | stool antigen test | – | 40 |
| 2007 | Isfahan | 200 b.i.d. | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 7 | 78 | 71.8 | 66 | 84.8 | UBT | No UBT (n=12) Poor Adherence (n=1) |
[25] |
| 2012 | Sari | 240 b.i.d. 14 days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. 14 day | p | 40 b.i.d. 14 day | 7 | 36 | 80.6 | 35 | 82.9 | UBT | No UBT (n=1) | [36] |
| 2012 | Sari | 240 b.i.d. 14days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. 14 day | p | 40 b.i.d. 14 day | 7* | 148 | 80.4 | 124 | 89.7 | UBT | No adherence (n=12) No UBT (n=11) |
[37] |
| 2010 | Yazd | 120 q.i.d. 14 days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d 14 day. | O | 20 b.i.d. 14 day | 7* | 92 | 79.3 | 82 | 89 | RUT/His tology | Lost (n=8) Side effect (n=2) |
[34] |
| 2011 | Sari | 240 b.i.d. | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. | O | 20 b.i.d. | 7* | 80 | 86.3 | 72 | 90.3 | UBT | No UBT (n=4) Side effect (n=1) Poor Adherence (n=3) |
[32] |
| 2015 | Sari | 200 b.i.d. | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 10 | 124 | 83.7 | 104 | 86.6 | UBT | Poor Adherence (n=4) Side effect (n=3) |
[38] |
| Furazolidone-Amoxicillin–bismuth quadruple therapy (14 day- treatment studies with 200 mg furazolidone b.i.d) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
| Bismuth (BPC) | Furazolidone | Amoxicillin | PPI | Days | ITT | PP% | ||||||||
| O/P | Dose | N | % | N | % | |||||||||
| 2001 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 63 | 84 | 59 | 90 | UBT | Lost (n=2) Side effect (n=11) |
[23] |
| 2003 | Rasht/Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 90 | 78.9 | 89 | 78 | UBT | Side effect (n=1) | [26] |
| 2004 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 50 | 92 | 49 | 93.8 | UBT | Side effect (n=1) | [21] |
| 2007 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 104 | 83.6 | 84 | 95.2 | UBT | Side effect (n=7) Poor Adherance (n=2) No UBT (n=7) Lost (n=4) |
[24] |
| 2007 | Isfahan | 200 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 78 | 73.1 | 66 | 82.6 | UBT | No UBT (n=5) Poor Adherance (n=3) |
[25] |
| 2011 | Qum | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 43 | 67.4 | 34 | 85.3 | UBT | Side effect (n=3) No UBT (n=4) Poor Adherance (n=2) |
[29] |
PPI, proton pump inhibitor; PP, per protocol; q.i.d., four times daily; b.i.d., twice daily; q.i.d., four times daily; q.d. daily; ITT, intention to treat; BPC, bismuth potassium citrate; O, omeprazole; P, pantoprazole.
*
= sequential type therapy.